Edwards Lifesciences
Clinical trials sponsored by Edwards Lifesciences, explained in plain language.
Edwards Lifesciences
EW
NYSE
A medical device company focused on heart valves and hemodynamic monitoring.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Heart shunt shows promise for easing heart failure symptoms Results expected Nov 2026 (estimated)
- New heart valve trial offers hope for patients with rare congenital defects Results expected Dec 2026 (estimated)
- New heart valve registry tracks Long-Term performance Results expected Dec 2026 (estimated)
- New Catheter-Based valve repair could help heart patients avoid surgery Results expected Dec 2026 (estimated)
- New heart valve fix offers hope for those too sick for surgery Results expected Feb 2027 (estimated)